Molecular Analysis for Therapy Choice (MATCH)
This phase II MATCH trial studies how well treatment that is directed by genetic testing
works in patients with solid tumors or lymphomas that have progressed following at least one
line of standard treatment or for which no agreed upon treatment approach exists. Genetic
tests look at the unique genetic material (genes) of patients'' tumor cells. Patients with
genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more
from treatment which targets their tumor''s particular genetic abnormality. Identifying these
genetic abnormalities first may help doctors plan better treatment for patients with solid
tumors, lymphomas, or multiple myeloma.
View more details from ClinicalTrials.gov.
For more information about a clinical trial, clinical trial eligibility, or informed consent, contact our research nurses by phone or email:
Please Note: Any eligibility criteria noted are subject to change. Our research nurses can provide you with the most current eligibility and exclusion criteria. Any study involvement to be undertaken must ultimately be determined on an individual basis.